US · TFX
Teleflex Incorporated
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Wayne, PA 19087-1603
- Website
- teleflex.com
Price · as of 2025-12-31
$121.77
Market cap 5.39B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $97.76 | -19.72% |
| Intrinsic Value(DCF) | $54.61 | -55.15% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $506.69 | +316.1% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $52.87 | $91.18 | $8.45 | $32.88 | $0.00 |
| 2012 | $72.84 | $54.43 | $0.00 | $0.00 | $0.00 |
| 2013 | $94.87 | $94.78 | $10.08 | $11.55 | $62.85 |
| 2014 | $111.01 | $112.31 | $0.00 | $16.49 | $73.34 |
| 2015 | $140.03 | $125.45 | $3.99 | $26.22 | $38.89 |
| 2016 | $184.05 | $157.00 | $8.19 | $26.89 | $61.32 |
| 2017 | $257.55 | $191.33 | $6.35 | $0.87 | $75.54 |
| 2018 | $275.86 | $191.53 | $24.01 | $7.99 | $94.59 |
| 2019 | $334.95 | $232.64 | $11.84 | $45.43 | $138.53 |
| 2020 | $410.40 | $253.75 | $0.00 | $31.81 | $43.47 |
| 2021 | $326.84 | $248.75 | $3.23 | $58.21 | $191.57 |
| 2022 | $218.03 | $192.94 | $1.40 | $49.98 | $58.51 |
| 2023 | $220.85 | $192.09 | $0.00 | $50.02 | $109.55 |
| 2024 | $138.31 | $138.10 | $0.00 | $22.23 | $15.51 |
| 2025 | $122.93 | $97.76 | $0.00 | $0.00 | $506.69 |
AI valuation
Our deep-learning model estimates Teleflex Incorporated's (TFX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $97.76
- Current price
- $121.77
- AI upside
- -19.72%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$54.61
-55.15% upside
Graham-Dodd
—
— upside
Graham Formula
$506.69
+316.1% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TFX | Teleflex Incorporated | $121.77 | 5.39B | -20% | -55% | — | +316% | -6.06 | 1.76 | 2.75 | 17.49 | — | -7.79 | 56.24% | 2.94% | -45.45% | -24.47% | 1.35% | -12.90% | 0.06 | 0.58 | 2.54 | 0.95 | -0.64 | -146824.00% | -3461.00% | -9972.00% | 0.03% | 0.13 | 0.03% | 1.10% | -6.70% | 36.82% | 90.40 | 3659.08 | 2.66 | 2.01 |
| ALKS | Alkermes plc | $30.10 | 4.97B | +85% | -49% | -41% | -85% | 20.62 | 2.74 | 3.38 | 13.49 | — | 2.87 | 86.31% | 17.21% | 16.37% | 14.72% | 20.15% | 10.64% | 0.04 | 20.69 | 2.06 | 1.70 | -1.57 | -3410.00% | -525.00% | -9987.00% | 0.01% | 0.00 | 0.05% | 0.00% | 0.00% | 6.08% | 17.58 | 8571.26 | 3.02 | 5.27 |
| ARWR | Arrowhead Pharmaceuticals… | $63.27 | 8.86B | +5,558% | +96,147% | -95% | — | 272.90 | 17.63 | 9.91 | 46.50 | — | 17.90 | 97.12% | 11.86% | -0.20% | 9.24% | 42.67% | 2.39% | 0.79 | 1.10 | 4.86 | 4.74 | 0.85 | -9976.00% | 2325815.00% | -12596.00% | 1.91% | 0.92 | 116.49% | 0.00% | 0.00% | 7.42% | 77.94 | 48.86 | 9.24 | 5.43 |
| BLCO | Bausch + Lomb Corporation | $18.30 | 6.48B | +52% | -60% | — | — | -18.50 | 1.01 | 1.28 | 20.11 | -138.78 | -4.09 | 58.71% | 3.12% | -7.06% | -5.45% | 1.41% | -2.56% | 0.83 | 0.37 | 1.55 | 0.84 | 8.72 | 1333.00% | 647.00% | 1186.00% | -1.01% | 0.15 | -0.59% | 0.00% | 0.00% | 0.00% | 72.33 | -174.25 | 2.25 | 0.92 |
| CRSP | CRISPR Therapeutics AG | $60.14 | 5.77B | -40% | -46% | — | +738% | -9.40 | 2.84 | 1556.91 | -7.08 | -19.15 | 2.84 | -6537.01% | -16191.40% | -16569.77% | -30.18% | -191.73% | -25.81% | 0.21 | — | 13.32 | 13.25 | -0.07 | 4908.00% | -8997.00% | 13911.00% | -6.33% | -2.31 | -116.70% | 0.00% | 0.00% | 0.00% | -6.83 | -11.23 | 1106.51 | 8.49 |
| KRYS | Krystal Biotech, Inc. | $275.64 | 8.06B | -24% | -34% | -72% | +4% | 36.57 | 6.14 | 19.25 | 39.75 | 28.57 | 6.14 | 92.61% | 41.45% | 52.64% | 18.91% | 42.60% | 17.14% | 0.01 | — | 9.95 | 9.28 | -2.90 | 12800.00% | 3394.00% | 5851.00% | 2.52% | 1.95 | 49.90% | 0.00% | 0.00% | 1.99% | 41.37 | 35.32 | 17.15 | 40.89 |
| MMSI | Merit Medical Systems, In… | $77.18 | 4.58B | +4% | -60% | -62% | -45% | 35.22 | 2.86 | 2.99 | 14.98 | 715.00 | 8.38 | 48.70% | 12.19% | 8.48% | 8.67% | 7.25% | 5.03% | 0.57 | 6.98 | 4.34 | 2.80 | 1.35 | 493.00% | 1175.00% | 1800.00% | 4.77% | 1.24 | 11.26% | 0.00% | 0.00% | 0.00% | 26.93 | 23.07 | 3.28 | 4.04 |
| PCVX | Vaxcyte, Inc. | $61.74 | 8.86B | — | — | — | — | -11.00 | 3.14 | — | -9.58 | -22.85 | 3.14 | 0.00% | — | — | -25.59% | -61.93% | -23.38% | 0.09 | — | 7.91 | 7.81 | -0.07 | 4816.00% | — | 4089.00% | -7.93% | -3.19 | -44.87% | 0.00% | 0.00% | 0.00% | -7.69 | -10.61 | — | 12.61 |
| PTCT | PTC Therapeutics, Inc. | $68.19 | 5.47B | +340% | +35% | -42% | +1,382% | 7.73 | -25.71 | 3.05 | 4.31 | — | -7.80 | 95.85% | 49.49% | 39.44% | -104.75% | -117.79% | 29.58% | -2.40 | 5.63 | 2.35 | 2.20 | -0.55 | -26448.00% | 11451.00% | -48603.00% | 13.31% | 0.73 | -98.57% | 0.00% | 0.00% | 41.37% | 4.47 | 5.45 | 2.21 | 1.69 |
| STVN | Stevanato Group S.p.A. | $15.52 | 4.24B | +118% | -45% | -52% | -68% | 31.27 | 3.57 | 4.54 | 21.56 | — | 3.80 | 27.38% | 14.60% | 10.67% | 12.64% | 7.41% | 7.29% | 0.31 | 23.48 | 1.84 | 1.32 | 1.33 | -2182.00% | 172.00% | -5314.00% | -3.15% | 0.33 | -9.88% | 0.29% | 9.00% | 0.29% | 33.16 | -33.86 | 4.84 | 4.68 |
| TGTX | TG Therapeutics, Inc. | $30.09 | 4.78B | +200% | +4,085% | -34% | +845% | 9.49 | 6.55 | 6.88 | 33.25 | 0.54 | 6.55 | 83.62% | 20.01% | 72.56% | 102.75% | 36.31% | 54.50% | 0.01 | 4.61 | 4.10 | 2.91 | -0.58 | 174667.00% | 8732.00% | -3840.00% | -0.59% | -0.16 | -7.36% | 0.00% | 0.00% | 5.57% | 33.32 | -164.45 | 6.67 | 6.21 |
About Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
- CEO
- Stuart A. Randle
- Employees
- 14.1K
- Beta
- 0.91
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($54.61 ÷ $121.77) − 1 = -55.15% (DCF, example).